$10 Million in Gifts Will Support Innovative Keystone Programs for Collaborative Discovery at Fox Chase Cancer Center
PHILADELPHIA (July 1, 2008) - Fox Chase Cancer Center announces $10 million in gifts in support of the Keystone Programs for Collaborative Discovery, a suite of new research initiatives designed to bring the power of team-based science to bear on some of the most significant problems in cancer research.
The gifts - from friends, members of the Fox Chase Board of Directors, and Fox Chase senior leadership - are a powerful demonstration of the momentum and excitement surrounding the Keystone Programs, first announced in February.
- $5 million from Alfred P. West Jr., CEO and chairman of SEI Investments in Oaks, PA, and his wife Loralee West.
- $2 million from Fox Chase board member Donald E. Morel Jr., Ph.D., chairman, president, and CEO of West Pharmaceutical Services, Inc. in Lionville, PA, and his wife Lauren Morel.
- $1 million from Fox Chase board member Louis E. Della Penna Sr., founder and former chairman of LDP Consulting Group, Inc., and his wife Carol Della Penna.
- $500,000 from Fox Chase board member David G. Marshall, chairman and CEO of Amerimar Realty Company, and his wife Sandy Marshall.
In addition, a $1.35 million bequest from the late Carolyn Galbraith Panicola will support the Keystone Program in Personalized Risk and Prevention.
At the heart of each of the four Keystone Programs is a self-organized group of scientists, clinicians, and other research professionals seeking to integrate and focus their combined expertise on important cancer problems.
"In each of their areas, these individuals have built some of the most successful enterprises in the country," said Michael V. Seiden, M.D., Ph.D., president and CEO of Fox Chase Cancer Center. "The unifying characteristic among them is that each has been able to foster interactive, creative, and energetic cultures able to adapt constantly to evolving needs. These are precisely the characteristics we aim to foster with the team-based approach of the Keystone Programs. We believe the next wave of major advances against cancer will depend on self-assembled teams of researchers from different fields effectively pooling their skills and resources. So we are honored to have these generous individuals as valued and particularly appropriate partners in this effort. We are extremely grateful to them for their vision and generosity in supporting the Keystone Programs for Collaborative Discovery."
Underscoring the precedence placed on the Keystone Programs by Fox Chase's senior leadership team, the gifts announced today include $100,000 from Dr. Seiden and $50,000 from J. Robert Beck, M.D., Chief Academic Officer at Fox Chase, and his wife Marjorie Beck, supporting a developing Keystone Program focused on head and neck cancers. The Keystone gifts made fiscal year 2008 - with $25 million raised - the most successful in private support in Fox Chase's history.
Mr. West is founder, chairman, and CEO of SEI Investments, a global assets management company dedicated to helping institutions and individuals more effectively manage their investments. A native Floridian, he received his B.S. in aerospace engineering from the Georgia Institute of Technology and an M.B.A. from the Wharton School of the University of Pennsylvania.
Dr. Morel is the chairman and CEO of West Pharmaceutical Services, Inc., which develops and applies technologies to enhance the delivery of new drug therapies and health care products to global markets. He joined the company in 1992 as Director of Research for North America. He became president and CEO in 2002, and chairman in 2003. He joined the Fox Chase Board of Directors in February 2008. The Morels' gift will fund an endowed chair in molecular imaging within the Keystone Programs.
Grateful for the care she received at Fox Chase, Ms. Panicola of Moorestown, NJ created a charitable remainder trust benefitting Fox Chase in 1998. The distribution from her estate will support the Keystone Program in Personalized Risk and Prevention.
Mr. Della Penna is founder and former chairman of LDP Consulting Group, Inc., a New Jersey-based employee-benefits consulting company. In 2005, Lou and Carol Della Penna presented two major gifts to Fox Chase: the $1 million Carol and Louis E. Della Penna Endowed Fund in Urologic Cancer Research and the $500,000 John A. Ridge, M.D., Ph.D., Endowed Surgical Oncology Fellowship. Their latest gift supports the Keystone Program in Personalized Kidney Cancer Therapy. Mr. Della Penna joined the Fox Chase Board of Directors in January 2008.
Mr. Marshall, a Fox Chase board member since 1994, is chairman and chief executive officer of Amerimar Realty Company. Marshall's wife, Sandra, has been involved with Fox Chase for a number of years as member of its Board of Advocates and the board of directors for the Center's Fox Chase Network, a nonprofit outreach program forming partnerships with a select group of community hospitals in Pennsylvania and New Jersey. Their Keystone gift comes on top of their previous $250,000 commitment.
The overarching goal of the Keystone Programs for Collaborative Discovery at Fox Chase Cancer Center is to accelerate the pace of medical progress against cancer. The programs were designed specifically to encourage and support the kind of creative team-based science at Fox Chase that will be required to solve the most challenging cancer problems.
The first four Keystone Programs for Collaborative Discovery are:
The Keystone Program in Personalized Risk and Prevention
- Goal: To discover molecular markers that predict cancer risk and to develop risk reduction strategies tailored to the profile and personal values of the individual
The Keystone Program in Epigenetics and Progenitor Cells
- Goal: To investigate two new views of the origins and maintenance of tumor cells with the aim of creating novel approaches to diagnosis, treatment, and prevention
The Keystone Program in Blood Cell Development and Cancer
- Goal: To identify the genes essential for blood precursor cells to give rise to the many distinct blood cell types, a critical step towards understanding blood cell cancers and improving the treatment of patients with leukemias and lymphomas
The Keystone Program in Personalized Kidney Cancer Therapy
- Goal: To investigate the mechanisms of kidney cancer metastasis and to uncover the molecular signals that anticipate how a kidney tumor will respond to therapies in order to optimize therapy for individual patients
More information about the Keystone Programs for Collaborative Discovery is available on the web at http://keystone.foxchaseprojects.org/.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.